EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
EyePoint, Inc. (EYPT)
Last eyepoint, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Clinical Differentiation Management attributes the rapid enrollment of Phase 3 wet AMD trials to strong Phase 2 data, which provided clinicians confidence in both efficacy and the safety profile. The 'DuraVu' clinical profile is differentiated by a multi-modal mechanism of action that addresses both VEGF-mediated leakage and IL-6-mediated inflammation, potentially improving long-term visual outcomes. Strategic positioning focuses on a best-in-class delivery technology designed for standard in-office injections every six months to significantly reduce treatment burden. Operational readiness is being scaled via a 41,000 square foot cGMP manufacturing facility in Massachusetts to support both NDA submission and future commercial supply. The appointment of a new Chief Commercial Officer with experience in major ophthalmology franchises signals a pivot toward becoming a fully integrated
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- Eyepoint Pharmaceuticals (EYPT) had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... [Yahoo! Finance]Yahoo! Finance
- Eyepoint Pharmaceuticals (EYPT) had its price target raised by Chardan Capital from $27.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
- Eyepoint Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 3/4/26 - Miss
EYPT
Analyst Actions
- 3/4/26 - Chardan Capital
EYPT
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 4
- 3/4/26 - Form 8-K
- EYPT's page on the SEC website